An Emerging Pharmaceutical Company

The successful leveraging of advanced capabilities and technologies initially for collaborations but more recently, also for proprietary purposes, is the essence of Evotec's heritage. In an effort that began several years ago, Evotec has successfully divested non-core assets for cash and retained assets most valuable for drug discovery.

Equally integral to the plan is the completed strategic merger with Renovis. It gives the Company what could be considered one of the strongest CNS related pipelines in the biotech industry, adding complementary drug hunting expertise and critical mass in a focused way, and enhances the likelihood of our pipeline's success.

With a newly balanced and enriched pipeline of three clinical programs, four advanced preclinical programs and a host of discovery projects, Evotec has emerged as a leader in drug discovery and development, not only in CNS but also in pain and in inflammation. Our 400+ employee base in the UK, in Germany, and now in the USA (Silicon Valley) presents an integrated discovery-through-development set of capabilities in core competencies that span assay development, screening, medicinal chemistry, fragment-based drug discovery and pharmacology.

In summary, drug discovery leadership across the CNS spectrum is now the foundation from which a broad and deep pipeline of opportunity will regularly emanate. Finally, access to the US capital market through our new NASDAQ ADR listing is expected to provide the Company improved access to the US financial markets and expand the liquidity of our investors' stockholdings.